title: [New oral anticoagulants: from theory to practice].
abstract: Physicians are confronted with many new antithrombotic drugs, either antiplatelet agents or new oral anticoagulants (NOAC). Targets of NOAC are specific (either anti-IIa or antiXa) and clinical studies have shown that NOAC are as efficacious and as safe as "old" anticoagulants (heparin, low molecular weight heparin, vitamin K antagonists); moreover they present some advantages. Indeed, NOAC have a wide therapeutic window and do not require laboratory monitoring. Therefore, it is very tempting to prescribe them on a large scale basis in patients at risk or having thromboembolic diseases. However, things are not so simple in the day-to-day practice and this review aims at answering in a brief and simplified manner to some questions.
authors: Service d'angiologie et d'hémostase HUG, 1211 Genève 14. philippe.demoerloose@hcuge.ch
authors: P
authors: P
authors: de Moerloose
authors: A
authors: A
authors: Casini
authors: F
authors: F
authors: Boehlen
authors: P
authors: P
authors: Fontana
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004347:Drug Interactions; D006801:Humans; D013514:Surgical Procedures, Operative; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D014812:Vitamin K; D003404:Creatinine